[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gouty-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gouty-arthritis":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":54,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100489857","phase-2-study-of-dapansutrile-tablets-in-subjects-with-an-acute-gout-flare-100489857",false,"NCT05658575","Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","A Multi-Center Phase 2\u002F3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Safety and Efficacy Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare","Inclusion Criteria:\n\n* Male and female subjects age 18 or older\n* Clinical diagnosis of gout according to the 2015 ACR\u002FEULAR Gout Classification Criteria:\n\nA) Diagnosis of gout must be confirmed in the target joint as indicated by either the presence of monosodium urate (MSU) crystals by microscopic evaluation of synovial fluid from the target joint or bursa OR by imaging evidence of urate deposition in the target joint or bursa at the Screening\u002FBaseline Visit\u002FStudy Day 1, or\n\nB) Documented history in the target joint or bursa ; or documented history of 2 or more gout flares in the previous 18 months\n\n* Confirmation of a gout flare in the target joint that began within 96 hours prior to the Screening\u002FBaseline Visit\n* Provide written informed consent and understand and comply with all trial requirements\n\nExclusion Criteria:\n\n* Presence of any palpable and visible tophi by physical examination\n* Has ≥ 4 joints with an acute gout flare at Screening\u002FBaseline\n* Presence of active rheumatoid arthritis or other acute inflammatory arthritis\n* Evidence\u002Fsuspicion of infectious\u002Fseptic arthritis\n* Clinically significant general pain or non-gout-related joint pain that would interfere with the subject's ability to accurately assess pain in the target joint\n* Known diagnosis of chronic kidney disease or known history of renal impairment\n* Positive test for severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection, if tested, within 4 weeks of the Screening\u002FBaseline\n* Active malignancy or recent malignancy with any systemic anti-cancer treatment\n* Has a hypersensitivity or allergy to OLT1177® or other drugs in its class\n* Hypersensitivity or allergy to paracetamol\u002Facetaminophen\n* Use of any prohibited concomitant medications\u002Ftherapies over the periods defined in the protocol or planned use of any prohibited concomitant medications\u002Ftherapies during the Treatment Period (including the use of paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or other pain medications within 12 hours prior to the Screening\u002F Baseline Visit\n* Use of any product containing paracetamol\u002Facetaminophen within 4 hours prior to the Screening\u002FBaseline Visit or planned use during the Treatment Period (with the exception of study-provided Rescue Medication \\[paracetamol\u002Facetaminophen\\], which is permitted after completion of the first target joint pain assessment on Study Day 4","ALL","18 Years",{"count":19,"type":20},300,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.",[27,28,29,30,31,32,33],"Acute Gout Flare","Gout Attack","Gout Flare","Gouty Arthritis","Gout","Arthritis","Joint Pain",[35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"gout","gouty arthritis","mono-articular arthritis","NLRP3","NLRP3 inhibitor","dapansutrile","OLT1177","joint pain","inflammation","gouty Inflammation","inflammasomes","IL-1 beta","IL-1 inflammation","autoinflammatory conditions","hyperuricemia","uric acid crystal","flare","small-molecule","therapeutic","RECRUITING","2026-03-09",{"date":57,"type":58},"2026-03-11","ACTUAL",{"date":60,"type":58},"2023-01-06",{"date":62,"type":20},"2027-01-31",{"name":64,"class":65},"Olatec Therapeutics LLC","INDUSTRY",40,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":21,"phases":77,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100584293","pharmacist-led-treat-to-target-urate-lowering-therapy-in-patients-with-gout-100584293","NCT06887452","Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients With Gout","Pharmacist-Led Treat-to-Target Urate Lowering Therapy in Patients in Gout (Pharm-UP) Study","Pham-UP","Inclusion Criteria:\n\n* US Veterans over the age of 18 years with physician-diagnosed\n* Documented hyperuricemia (SU \\>6.8 mg\u002FdL)\n* Satisfy ACR\u002FEULAR gout classification criteria\n* Report 1 or more flares in the prior 6 months\n* Receipt of a new ULT prescription (allopurinol or febuxostat) initiated by a primary care provider or longer term ULT but otherwise satisfy the flare\u002FSU criteria\n\nExclusion Criteria:\n\n* Any patient intolerant or unable to take ULTs (allopurinol or febuxostat)\n* Patients with a rheumatology encounter within the prior 3 months",{"count":76,"type":20},310,[78],"NA","This study will compare two different approaches to manage medications that lower uric acid levels. This study will be conducted at five VA medical centers across the United States and will take 4-5 years to complete. Individual participation will last up to two years.",[31,30],"NOT_YET_RECRUITING","2026-02-17",{"date":84,"type":58},"2026-02-19",{"date":86,"type":20},"2026-10-01",{"date":88,"type":20},"2031-03-30",{"name":90,"class":91},"VA Office of Research and Development","FED",5]